Inhibitor Therapeutics, Inc. (INTI)
OTCMKTS · Delayed Price · Currency is USD
0.0800
-0.0070 (-8.05%)
Jul 27, 2026, 4:00 PM EST

Inhibitor Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-3.45-3.43-3.66-3.4-0.66-0.33
Net Income
-3.35-3.3-3.34-3.0311.92-0.5
Earnings Per Share
-0.02-0.02-0.02-0.020.03-0.00
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1.292.385.618.8411.950.03
Total Debt
0.060.06--0.410.23
Net Cash (Debt)
1.232.315.618.8411.54-0.2
Net Cash Growth
-70.91%-58.73%-36.57%-23.40%--
Net Cash Per Share
0.010.010.030.050.03-0.00

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-3.03-3.23-3.23-2.711.74-0.22
Free Cash Flow
-3.03-3.23-3.23-2.711.74-0.22
Free Cash Flow Growth
------

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
----3.12-